Global Heparin Market 2016-2020

ヘパリンの世界市場:未分画へパリン、低分子へパリン

◆タイトル:Global Heparin Market 2016-2020
◆商品コード:IRTNTR9053
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年3月17日
◆ページ数:73
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ヘパリンの世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ヘパリンパイプライン製品、ヘパリン原薬市場、ヘパリンの世界市場規模及び予測、製品別分析、地域別分析/市場規模、購買基準、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

・エグゼクティブサマリー
・市場概観
・業界の構造分析
・ヘパリンパイプライン製品
・ヘパリン原薬市場
・ヘパリンの世界市場:市場規模及び予測
・ヘパリンの世界市場:製品別分析
・ヘパリンの世界市場:地域別分析
・ヘパリンの世界市場:アジア市場規模
・ヘパリンの世界市場:アメリカ市場規模
・ヘパリンの世界市場:ヨーロッパ市場規模
・ヘパリンの世界市場:成長要因
・ヘパリンの世界市場:課題
・購買基準
・市場動向
・競争状況
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Heparin

Heparin, a disaccharide anticoagulant or blood thinner, prevents the formation of blood clots. It is produced in the body by basophils and mast cells. It is stored within mast cells and secreted at the injury site. Though it has no effect on already formed clots, it enables the body’s natural clot lysis mechanisms to dissolve clots. It can also be taken from outside as a drug. Heparin can be derived from natural sources such as pig intestine and bovine lungs.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.
• UFH: It is directly obtained from natural sources, without undergoing any fractionation.
• LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.

Apart from these, another category of molecules, ULMWH are available. They are structurally related to LMWHs, but differ in the composition of monosaccharides and oligosaccharides. Therefore, they have different average molecular weights from LMWH.

Technavio’s analysts forecast the global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global heparin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Heparin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline plc (GSK)
• Leo Pharma A/S
• Pfizer Inc.
• Sanofi

[Other prominent vendors]
• Alchemi
• Baxter
• BMS
• Boehringer Ingelheim
• Celgene
• Cosmo Pharmaceuticals
• Dr.Reddy’s Laboratories
• Eisai
• Fresenius
• GSK
• Hospira
• Laboratorios Rovi Pharmaceuticals
• Lee’s Pharmaceutical
• Momenta Pharmaceuticals
• Mylan
• Novartis
• Ockham Biotech
• Perospher
• PolyMedix
• Portola Pharmaceutical
• ProStrakan Group
• Sagent Pharmaceticals
• Sigma Tau Pharmaceuticals
• UCB
• Urigen Pharmaceuticals

[Market driver]
• Growing prevalence of diseases
• For a full, detailed list, view our report

[Market challenge]
• Extensive use of generic products due to patent expirations
• For a full, detailed list, view our report

[Market trend]
• Expected exploitation of new therapeutic use
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Key buying criteria

PART 05: Heparin: An overview
• Mechanism of action (MOA)
• Limitations of heparin use
• Clinical uses of heparin
• Branded drug profiles

PART 06: Pipeline portfolio
• LMW Heparin MMX
• URG101
• Heparin
• Heparin plus dexoyribonuclease (DNAse)
• Heparin plus other inhaled drug

PART 07: Market landscape
• Global anticoagulant drugs market
• Global heparin market
• Five forces analysis

PART 08: Heparin use in CPB surgery
• CPB
• Heparin use in CPB surgery
• Global heparin market in CPB surgeries

PART 09: Heparin API market
• China: Heparin API market

PART 10: Suppliers of crude heparin
• FDA guidance for heparin suppliers

PART 11: Market segmentation by product type
• UFH
• LMWH
• ULMWH

PART 12: Market segmentation by ROA
• IV injection/infusion
• SC injection

PART 13: Geographical segmentation
• Global heparin market by geographical segmentation 2015-2020
• Heparin market in EMEA
• Heparin market in Americas
• Heparin market in APAC

PART 14: Market drivers
• Growing prevalence of diseases
• Increase in supply chains of crude heparin
• Reintroduction of bovine heparin by US FDA

PART 15: Impact of drivers

PART 16: Market challenges
• Extensive use of generic products due to patent expirations
• Risk of side-effects
• Shortage of crude heparin
• Threat of adulteration
• Presence of well-established oral anticoagulants

PART 17: Impact of drivers and challenges

PART 18: Market trends
• Expected exploitation of new therapeutic use
• Strategic alliances
• Increase in R&D
• Entry of new heparin antidotes

PART 19: Vendor landscape
• Competitive scenario
• Market analysis 2015
• Sanofi
• Pfizer
• Aspen
• LEO Pharma
• Other prominent vendors

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for heparin drugs
Exhibit 03: Differences between porcine heparin and bovine heparin
Exhibit 04: Process of blood coagulation
Exhibit 05: Mechanism of action of heparin
Exhibit 06: Pipeline portfolio: Heparin drugs
Exhibit 07: Market share of global heparin market in global anticoagulant drugs market 2015
Exhibit 08: Global anticoagulant drugs market 2015-2020 ($ billions)
Exhibit 09: Global heparin market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Global heparin market in CPB surgeries 2015-2020 ($ millions)
Exhibit 12: Process of crude heparin production in China
Exhibit 13: Segmentation of global heparin market by product type 2015
Exhibit 14: Segmentation of global heparin market by ROA
Exhibit 15: Segmentation of global heparin market based on geography 2015
Exhibit 16: Global heparin market revenue by geography 2015-2020 ($ billions)
Exhibit 17: Global heparin market by geography 2015-2020
Exhibit 18: Heparin market in EMEA 2015-2020 ($ billions)
Exhibit 19: Heparin market in Americas 2015-2020 ($ billions)
Exhibit 20: Heparin market in APAC 2015-2020 ($ billions)
Exhibit 21: Global heparin market: YoY growth and revenue based on geography 2015-2020
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
Exhibit 25: Geographical segmentation of Lovenox 2015
Exhibit 26: Sanofi: Key takeaways
Exhibit 27: Pfizer: YoY revenue and growth rate of Fragmin 2013-2015 ($ millions)
Exhibit 28: Geographical segmentation of Fragmin by revenue 2015
Exhibit 29: Pfizer: Key takeaways
Exhibit 30: Aspen: Key takeaways
Exhibit 31: LEO Pharma: Key takeaways



【掲載企業】

GlaxoSmithKline plc (GSK), Leo Pharma A/S, Pfizer Inc., Sanofi, Alchemi, Baxter, BMS, Boehringer Ingelheim, Celgene, Cosmo Pharmaceuticals, Dr.Reddy's Laboratories, Eisai, Fresenius, GSK, Hospira, Laboratorios Rovi Pharmaceuticals, Lee's Pharmaceutical, Momenta Pharmaceuticals, Mylan, Novartis, Ockham Biotech, Perospher, PolyMedix, Portola Pharmaceutical, ProStrakan Group, Sagent Pharmaceticals, Sigma Tau Pharmaceuticals, UCB, Urigen Pharmaceuticals.

【資料のキーワード】

ヘパリン、未分画へパリン(UFH)、低分子量ヘパリン(LMWH)、ヘパリン原薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ヘパリンの世界市場:未分画へパリン、低分子へパリン]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆